Bio-Rad Laboratories (BIO) reported Q4 adjusted net income late Thursday of $2.90 per diluted share, down from $3.10 a year ago.

Analysts polled by FactSet expected $2.87.

Revenue for the quarter that ended Dec. 31 was $667.5, down from $681.2 million a year ago.

Analysts surveyed by FactSet expected $679.3 million.

For 2025, the company expects non-GAAP, currency-neutral revenue growth of 1.5% to 3.5% and non-GAAP operating margin of 13.0% to 13.5%.

Bio-Rad shares were down about 4% in extended trading.